摘要:
Provided herein is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., R1, R2, X1, X2, Y1, Y2, Y3, Y4, Y5, Y6, Y7, and Y8) are as disclosed herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of using the compounds, pharmaceutically acceptable salts thereof and pharmaceutical compositions of the foregoing, e.g., to treat a neurological or psychiatric disease or disorder.
摘要:
The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water-soluble oligomer.
摘要:
The present invention relates to compounds of the formula I wherein R1, R2, R3, R4, X and Y have the meanings given in the description. The compounds have an action which is immunomodulating and inhibits or regulates the release of IL-1β and/or TNF-α. They can therefore be used for treatment of diseases connected with a disturbance in the immune system.
摘要:
The present invention relates to new oxepine modulators of H1 receptors and/or inhibitors of mast cell degranulation, pharmaceutical compositions thereof, and methods of use thereof.
摘要:
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.
摘要:
Process for the preparation of olopatadine (I), which comprises reacting a compound of formula (V) in the presence of a palladium catalyst to, provide a compound of formula (VI), wherein the acid protecting group is removed to provide the compound of formula (I) and if desired, transformation into its salts.
摘要:
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.
摘要:
The present invention provides a compound of the formula (I) wherein R1 is —H, —OH, —O(C1–C4 alkyl), —OCOC6H5, —OCO(C1–C6 alkyl), or —OSO2(C2–C6 alkyl); R0, R2 and R3 are each independently —H, —OH, —O(C1–C4 alkyl), —OCOC6H5, —OCO(C1–C6 alkyl), —OSO2(C2–C6 alkyl) or halo; R4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino; n is 2 or 3; X is —S— or —HC═CH—; G is —O—, —S—, —SO—, SO2, or —N(R5)—, wherein R5 is —H or C1–C4 alkyl; and Y is —O—, —S—, —NH—, —NMe-, or —CH2—; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions thereof, optionally in combination with estrogen and progestin; methods of inhibiting a disease associated with estrogen deprivation; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.
摘要:
Described are amino substituted hydroxyphenyl benzophenone derivatives of formula (I), wherein R1, and R2 independently from each other are; C1-C20alkyl; C2-C20-alkenyl; C3-C10cycloalkyl; C3-C10cycloalkenyl; or R1, and R2 together with the linking nitrogen atom form a 5- or 6-membered heterocyclic ring; n1 is a number from 1 to 4; when n1=1, R3 is a saturated or unsaturated heterocyclic radical; hydroxy-C1-C5alkyl; cyclohexyl optionally substituted with one or more C1-C5alkyl; phenyl optionally substituted with a heterocyclic radical, aminocarbonyl or C1-C5alkylcarboxy; when n1 is 2, R3 is an alkylene-, cycloalkylene- or alkenylene radical which is optionally substituted by a carbonyl- or carboxy group; o R3 together with A forms a bivalent radical of the formula (Ia), wherein n2 is a number from 1 to 3; when n1 is 3, R3 is an alkanetriyl radical; when n1 is 4, R3 is an alkanetetrayl radical; A is —O—; or —N(R5)—; and R5 is hydrogen; C1-C5alkyl; or hydroxy-C1-C5alkyl. The compounds are useful as UV filters in sunscreen applications.
摘要翻译:描述了式(I)的氨基取代的羟基苯基二苯甲酮衍生物,其中R 1和R 2彼此独立地为: C 1 -C 20烷基; C 1 -C 20烷基; C 2 -C 20 - 烯基; C 3 -C 10环烷基; C 3 -C 10环烯基; 或R 1和R 2与连接氮原子一起形成5-或6-元杂环; n 1是1至4的数; 当n 1 = 1时,R 3 3是饱和或不饱和杂环基; 羟基-C 1 -C 5烷基; 任选被一个或多个C 1 -C 5烷基取代的环己基; 任选被杂环基取代的苯基,氨基羰基或C 1 -C 5烷基羧基; 当n 1是2时,R 3是任选被羰基或羧基取代的亚烷基 - 亚环烷基 - 或亚烯基; R 3与A一起形成式(Ia)的二价基团,其中n 2是1至3的数; 当n 1为3时,R 3为烷三基; 当n 1为4时,R 3为烷基乙酰基; A为-O- 或-N(R 5) - ; 并且R 5是氢; C 1 -C 5烷基; 或羟基-C 1 -C 5烷基。 这些化合物可用作防晒霜中的紫外线过滤器。
摘要:
Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).